Chemotherapeutic treatment for cancer has been successful in prolonging survival but may also lead to the development of second cancers. Two case-control studies presented here There are a number of reasons to study multiple primary cancers. These include the elucidation of cancer etiology and the assessment of any iatrogenic effects resulting from therapy given for the initial cancer. Although chemotherapeutic treatment has helped to prolong survival after cancer diagnosis [1], these agents not only kill tumor cells but may also be carcinogenic themselves [2] . Thus, longer survival combined with the carcinogenic potential of chemotherapeutic drugs raises the possibility that such treatment may be involved in the development of second primaries.
There are a number of reasons to study multiple primary cancers. These include the elucidation of cancer etiology and the assessment of any iatrogenic effects resulting from therapy given for the initial cancer. Although chemotherapeutic treatment has helped to prolong survival after cancer diagnosis [1] , these agents not only kill tumor cells but may also be carcinogenic themselves [2] . Thus, longer survival combined with the carcinogenic potential of chemotherapeutic drugs raises the possibility that such treatment may be involved in the development of second primaries.
There is relatively little information on the relationship between chemotherapy and the development of second cancers among women with an initial breast cancer. Curtis et al. [3] have shown that the alkylating agents given for breast cancer therapy are associated with an increased risk of developing acute nonlymphocytic leukemia. Horn et al. [4] found an elevated but not statistically significant association between such treatment and the development of a contralateral breast cancer. Others, however, have found chemotherapy given for breast cancer to be associated with a lowered occurrence of second breast primaries [5] [6] [7] . Breast cancer chemotherapy has been available since the early 1960s. The adjuvant chemotherapy in common use today began in the mid-1970s, and in recent years hormonal therapy has become increasingly common, particularly for the treatment and prophylactic prevention of metastases.
We have conducted two case-control studies that have been designed to look at the broad issue of the risk factors for second breast primaries developing among breast cancer patients. Both of these studies have included an assessment of the effects of therapy. The results presented here focus primarily on the preliminary findings concerning the effects of chemotherapy from the second of these two studies.
METHODS Hospital Records Study
The methods used in this study have been described in detail elsewhere [7, 8] . Briefly, a case-control study was conducted using hospital records as the sole source of information. Both cases and controls were identified from the records of the Connecticut Tumor Registry (CTR). Cases were women who had been newly diagnosed with a contralateral breast primary in one of eight Connecticut hospitals between July 1, 1975, and December 31, 1983 , and who had been diagnosed with an initial breast cancer in one of the same eight hospitals since 1935. Eligible controls were women who were at risk of developing a contralateral cancer, i.e., women who had been diagnosed with an initial breast cancer in one of the eight hospitals since 1935 but had not developed a second breast cancer nor had had a prophylactic mastectomy of the contralateral breast. Both independent carcinoma in situ and invasive lesions were included in the study. Because of difficulties in the differential diagnosis of second primary cancers versus metastatic spread of the first cancer in the presence of distant metastases or an ipsilateral chest wall recurrence, women with either of these two conditions were excluded from the study.
From the records of the CTR, 309 women were identified as meeting the eligibility criteria for cases. Hospital records were obtained for 300 (97.1 percent) of these women. A random sample of 309 women was chosen as the control group from among 7,830 women identified as meeting the above criteria. Hospital records were obtained for 289 (93.5 percent) of these women. Seven cases and 23 controls were subsequently excluded from the study as ineligible due to a record of distant metastases, ipsilateral chest wall recurrence, or a prophylactic mastectomy in the hospital record. The diagnosis of the second primary was a pre-malignant condition not routinely reported to the Registry in one case and was made on clinical, not histologic, grounds for an additional two cases. These women were also excluded. Finally, two women selected as controls were found to have had a contralateral breast cancer that was diagnosed during the study period but had not yet been reported to the Registry. These two women were excluded as controls and included in the case group. Thus, 292 cases and 264 controls were included in that study.
Interview Study
As in the hospital records study, a case-control approach was used to sample efficiently from a theoretical cohort that consisted of women with a first breast cancer who would have been followed for up to 50 years for the development of a second breast primary. The records of the Connecticut Tumor Registry, which date back to 1935, again offered a unique opportunity to assemble such a cohort. In this study, eligible cases were women who were diagnosed with a contralateral breast primary between July 1, 1983, and September 30, 1986 , and who had been diagnosed with an initial breast cancer since 1935. Cases were required to be residents of Connecticut at the time of both diagnoses. Thus, cases are representative of that portion of the theoretical cohort whose second breast cancers were recently diagnosed.
The controls in these two studies are representative of the portion of the theoretical cohort who did not develop a second breast cancer. As with the cases, the first breast cancer in these women had developed at any time since 1935. Their follow-up was censored at one of the reference dates during the study period. Seven reference dates were defined, each being the mid-point of successive six-month segments of the study period, i.e., April 15, 1984 April 15, , 1985 April 15, , and 1986 , and October 15, 1983, 1984, 1985, and 1986 . Since the cases were expected to develop relatively uniformly over the study period, an equal number of controls were randomly selected into the study at each specified reference date from among all women meeting the additional eligibility criteria outlined below. A control had to be alive as of the reference date, a resident of Connecticut both at the time of the initial cancer diagnosis and the reference date, and, as of the reference date, never have had a contralateral breast cancer nor a prophylactic mastectomy of the contralateral breast.
A complete pathology review of all initial and contralateral cancers is being conducted for this study. Thus, women with ipsilateral chest wall recurrences and distant metastases are not being excluded a priori. Information on reproductive and menstrual history, family history, health care practices, medical history, smoking history, and diet is being collected through interviews with study subjects. Information on tumor characteristics and treatment is being collected through review of histologic specimens, hospital records, and outpatient medical records. This paper reports on 305 cases and 273 controls interviewed during the first two years of the study.
Analysis
Crude odds ratios (OR) were estimated and corresponding confidence intervals (CI) were obtained using Woolfs method [9, 101] . Unconditional logistic regression analyses were performed in order to obtain adjusted odds ratios (aOR) [11, 12] . Formal statistical assessment of interaction was performed under a multiplicative model by including cross-product terms in hierarchical logistic models [12, 13] . Estimates of the magnitude of effect modification are expressed as the ratio of the odds ratios (ROR), i.e., for dichotomous factors X and Y, the odds ratio for the relationship between factor X and the development of a second cancer for women with factor Y divided by the corresponding odds ratio for women without factor Y. Table   1 presents the associations between the administration of chemotherapy and the development of a contralateral cancer as observed in the two studies. Both studies suggest a significant decrease in second breast primaries among those having received such treatment (OR = 0.3, 95 percent CI: 0.2-0.7 and OR = 0.6, 95 percent CI: 0.4-0.9, for the hospital records study and the interview study, respectively). It should be noted that here chemotherapy treatment is used in a broad sense and includes both cytotoxic and hormonal drug therapy. In addition, only chemotherapy administered before the second cancer diagnosis for cases or the reference date for controls is included. The estimates for the interview study are not adjusted for possible confounding effects of other factors, most particularly, stage of disease and time since administration. However, the crude and adjusted estimates (adjusted for both stage of disease and time since diagnosis/administration as well as other factors) in the hospital record study are similar, suggesting minimal confounding effects.
RESULTS
The protective effect associated with having received chemotherapy did not change significantly over time in either study (ROR = 1. 1, 95 percent CI: 0.7-1.6, and ROR = 0.8, 95 percent CI: 0.7-1.1 for a two-year differential in time since initial cancer diagnosis, in the hospital records and interview studies, respectively). Figure 1 presents the fitted odds ratios and 95 percent confidence bands for the modelled effects of this interaction based on data from the interview study. About three years after initial cancer diagnosis, the protective effect becomes statistically significant.
Specific information on the drugs, dosages, and duration of administration is currently available for 47 percent of those subjects, in the interview study, who reported receiving chemotherapy. Table 2 presents the associations between the two main types of chemotherapeutic drugs and the development of a second breast cancer. The protective effect of having received chemotherapy is present for both cytotoxic and hormonal therapy. The only statistically significant effect, however, is for cytotoxic therapy when adjustment for having received hormonal therapy is not made (OR = 0.5, 95 percent CI: 0.3-1.0). Table 3 presents the average cumulative dose and the average dose per administration for each of the four drugs in most common use today. The dosages administered to cases and controls were very similar, and no statistically significant differences were observed. In addition, the duration of therapy was similar for cases and controls, with a mean of approximately 11 months for cytotoxic therapy and 17 months for hormonal therapy.
In the hospital record study, an intriguing interaction between chemotherapy and Quetelet's index (a measure of body build) was observed [7] . This interaction suggests that, for women of low or normal body weight, having received chemotherapy was associated with a significant decrease in the risk of a contralateral cancer. For overweight women, however, a nonsignificant but detrimental effect was seen. In the interview study, the data were also examined for evidence of this interaction, and similar effect modification was observed when hormonal therapy and Quetelet's index based on reported weight at age 25 were considered (ROR = 2.4, 95 percent CI: 1.0-5.9 for a 2.5-unit differential in Quetelet's index) (Fig. 2) . No such effect 
DISCUSSION
The preliminary results from the interview study presented here confirm the previous findings of the hospital record study [7] . Chemotherapy administered for breast cancer appears to be protective against the development of a contralateral breast cancer. Furthermore, while not fully evaluated yet, this protective effect is demonstrable for up to ten years after diagnosis and appears to be associated with both hormonal and cytotoxic therapy. More conclusive evidence is needed regarding the possible modification of this effect by body build.
Previous reports of the effects of chemotherapy on the development of a contralateral breast primary have been limited. With an average of three years of follow-up, Herring et al. [6] the occurrence of contralateral breast cancers in the first two years of follow-up among breast cancer patients receiving tamoxifen in a randomized trial. The only report of an increase in contralateral breast cancers following chemotherapy comes from a case-control analysis of data from the Connecticut Tumor Registry [4] . This elevation in risk, however, was not statistically significant. The preliminary results of the interview study reported here suggest that both cytotoxic and hormonal drug therapy are associated with a reduction in second breast primaries. The effects for each type of drug alone are not statistically significant; however, there was low statistical precision because of the small numbers of subjects currently included in the analysis. The information of the drugs administered in the hospital records study was limited, since most chemotherapy is given on an outpatient basis, and the overall number of subjects known to be receiving any type of chemotherapy in that study was small. While the estimates for particular types of drugs were imprecise (primarily as a result of (a) missing information on type of drug for 19 percent of subjects and (b) 62 percent of subjects receiving hormonal therapy also received cytotoxic therapy), the results of that study also suggested a decrease in second breast primaries for both cytotoxic and hormonal therapy [7] . The much larger proportion of subjects receiving chemotherapy in the interview study as compared to the hospital records study most probably reflects the more recent time period of the interview study and the increasing use of chemotherapy in medical practice. Unlike most other studies to date, the present two studies, particularly the interview study, have the advantage of a much longer period of observation after the administration of chemotherapy. Because of the study design, which relies on an internal comparison, differences in survival between women who develop second primaries and women who do not cannot affect the results reported here. Both cases and controls are survivors of their initial disease. In both studies a significant protective effect of having received chemotherapy was observed. The majority of the chemotherapy administered to patients in these two studies was given in the first year or so after the initial cancer diagnosis. The protective effect observed for chemotherapy was not strongly affected by the time elapsing since initial cancer diagnosis, a proxy measure for the time since administration. In the interview study, however, a larger proportion of chemotherapy treatment was given after the first year following diagnosis, since exclusions were not made for women with chest wall recurrences or distant metastases. Further analyses will consider more precisely the time since administration. In the interview study, the protective effect of having received chemotherapy continued for up to ten years after the initial cancer diagnosis. Conclusions regarding the effects of chemotherapy over time were limited to the first ten years since very few subjects followed for a longer period had received such treatment. In the years to come, study of the effects of having received chemotherapy after ten years of follow-up will be of particular interest since the latency period between tumor induction and clinical detection has been estimated to be on the order of ten years for solid tumors [ 14] . It may be that what we are seeing now is the systemic effects of chemotherapy in killing developing tumors. Any carcinogenic potential of chemotherapy treatment may not yet be observable. In addition, while the current evidence suggests that an added benefit of chemotherapy is the prevention of second primaries among those currently selected by medical practice to receive such therapy, we would not advocate the administration of chemotherapy to a wider group of patients without first conducting controlled clinical trials to evaluate such practice.
The findings from the hospital records study suggested that the effects of chemotherapy were modified by body build, such that receiving chemotherapy was found to be protective against the development of a contralateral cancer among women of normal or reduced body weight but was associated with an elevated risk among overweight women [7] . This finding was considered intriguing since toxins may collect in adipose tissue and the contralateral breast tissue may be especially susceptible to chemotherapeutic agents, particularly cytotoxic agents which not only kill tumor cells but may also be carcinogenic. In that study, it was not possible to evaluate whether this interaction was the result of a particular type of drug. Interestingly, the interview study found similar effect modification for hormonal therapy but not for cytotoxic therapy. The hypothesis that the increase in risk associated with chemotherapy in overweight women was due to the collection of drugs in adipose tissue seems somewhat less tenable for the hormonal agents than for the cytotoxic agents. Additional issues suggest that these associations should be interpreted with caution. The interaction in the hospital records study was with Quetelet's index based on weight at time of first diagnosis, usually measured directly rather than reported by the patient. In the interview study, the interaction with hormonal therapy was statistically significant when Quetelet's score was based on weight at age 25. When usual adult weight was used, the curve was relatively flat. This somewhat discrepant finding may be related to misclassification; however, the manner in which this misclassification enters the picture is unclear. It is not known whether a self-report of weight at age 25 or a self-report of usual adult weight would be more precisely recalled and thus be a more accurate reflection of true body build. An alternative explanation would simply be that the finding of an interaction between one type of therapy and a particular measure of body build was due to chance. Indeed, false-negative and false-positive findings are common when examining interaction effects [15] . Finally, the tentative nature of the interaction, as demonstrated in Table 4 , adds to the need for further caution in interpreting this effect. Once the remaining information of the specifics of treatment is available, we expect to be able to evaluate this interaction more thoroughly.
